Humanized antibodies that recognize beta amyloid peptide
OwnerDale B. Schenk, Ted Yednock +1inventors
InventorsDale B. Schenk, Ted Yednock, Guriq Basi
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
Claims30
Humanized 3D6 antibody.
A humanized antibody, or fragment thereof, comprising a humanized light chain comprising three light chain complementarily determining regions (CDRs) from the mouse monoclonal antibody 3D6 and a light chain variable region framework sequence from a human immunoglobulin light chain;
- and a humanized heavy chain comprising three heavy chain CDRs from the mouse monoclonal antibody 3D6 and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain;
- wherein the light chain CDRs have the following amino acid sequences:
- light chain CDR1:
- Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn (residues 24-39 of SEQ ID NO:2)
- light chain CDR2:
- Leu Val Ser Lys Leu Asp Ser (residues 55-61 of SEQ ID NO:2)
- light chain CDR3:
- Trp Gln Gly Thr His Phe Pro Arg Thr (residues 94-102 of SEQ ID NO:2)
- and the heavy chain CDRs have the following amino acid sequences:
- heavy chain CDR1:
- Asn Tyr Gly Met Ser (residues 31-35 of SEQ ID NO:4)
- heavy chain CDR2:
- Ser Ile Arg Ser Gly Gly Gly Arg Thr Tyr Tyr Ser Asp Asn Val Lys Gly (residues 50-66 of SEQ ID NO:4) and,
- heavy chain CDR3:
- Tyr Asp His Tyr Ser Gly Ser Ser Asp Tyr (residues 99-107 of SEQ ID NO:4).
A humanized antibody or fragment thereof comprising a humanized light chain variable region having complementarily determining regions (CDRs) from SEQ ID NO:2 and variable region framework sequence from a human immunoglobulin light chain having substantial sequence identity to the sequence of SEQ ID NO:6, and a humanized heavy chain variable region having CDRs from SEQ ID NO:4 and variable region framework sequence from a human immunoglobulin heavy chain having substantial sequence identity to the sequence of SEQ ID NO:9.
A humanized antibody or fragment thereof comprising a humanized light chain variable region sequence substantially identical to SEQ ID NO:5 and having a substitution in at least one of positions L7, L10, L12, L15, L17, L39, L45, L63, L78, L83, L85, L100 or L104, and a humanized heavy chain variable region sequence substantially identical to SEQ ID NO:8 and having a substitution in at least one of the positions H3, H5, H13, H16, H19, H40, H41, H42, H44, H72, H77, H84 or H108.
A polynucleotide comprising a sequence that codes for a light chain variable region having complementarily determining regions (CDRs) from SEQ ID NO:2 and variable region framework sequence from a human immunoglobulin light chain having substantial sequence identity to the sequence of SEQ ID NO:6.
A polynucleotide comprising a sequence that codes for a light chain variable region sequence substantially identical to SEQ ID NO:5 and having a substitution in at least one of positions L7, L10, L12, L15, L17, L39, L45, L63, L78, L83, L85, L100 or L104.
A polynucleotide comprising a sequence that codes for a heavy chain variable region having CDRs from SEQ ID NO:4 and variable region framework sequence from a human immunoglobulin heavy chain having substantial identity to the sequence of SEQ ID NO:9.
A polynucleotide comprising a sequence that codes for a heavy chain variable region sequence substantially identical to SEQ ID NO:8 an having a substitution in at least one of the positions H3, H5, H13, H16, H 19, H40, H41, H42, H44, H72, H77, H82 H83, H84 or H108.
Dependencies are inferred from the claim text.